DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Hodgkin Disease
Lymphoma, Non-Hodgkin

Interventions: Drug: Relatlimab
Drug: Nivolumab

First Posted Date: 2022-02-24

Last Posted Date: 2025-05-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 68

Registration Number: NCT05255601

Locations: 🇮🇹
Local Institution - 0010, Aviano, Italy
🇮🇹
Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
🇮🇹
Azienda Ospedaliero Universitaria Meyer, Florence, Italy

and more 72 locations

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2022-02-22

Last Posted Date: 2023-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 501

Registration Number: NCT05250817

Locations: 🇺🇸
RTI Health Solutions, Research Triangle Park, North Carolina, United States

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Phase 1

Recruiting

Conditions: Pancreatic Adenocarcinoma
Non Small Cell Lung Cancer
Advanced Solid Tumor
Malignant Peripheral Nerve Sheath Tumors
Mesothelioma
Solid Tumor

Interventions: Drug: MRTX1719

First Posted Date: 2022-02-18

Last Posted Date: 2025-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 320

Registration Number: NCT05245500

Locations: 🇺🇸
Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States
🇺🇸
Cancer and Hematology Centers of Western Michigan, Norton Shores, Michigan, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 19 locations

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Terminated

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma

Interventions: Drug: BMS-986403
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-02-17

Last Posted Date: 2023-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT05244070

Locations: 🇺🇸
Local Institution - 0026, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 0007, Boston, Massachusetts, United States
🇺🇸
Local Institution - 0005, Birmingham, Alabama, United States

and more 5 locations

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Atazanavir
Drug: Cobicistat
Drug: Atazanavir/Cobicistat Mini-tablet

First Posted Date: 2022-02-11

Last Posted Date: 2022-10-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT05236738

Locations: 🇺🇸
Local Institution - 0001, Miami, Florida, United States

A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation

Recruiting

Conditions: Non-Valvular Atrial Fibrillation (NVAF)

First Posted Date: 2022-02-10

Last Posted Date: 2023-12-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 720

Registration Number: NCT05232643

Locations: 🇮🇹
Local Institution - 0001, Milano, MI, Italy

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Completed

Conditions: Multiple Myeloma

First Posted Date: 2022-02-01

Last Posted Date: 2023-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT05217082

Locations: 🇺🇸
Local Institution - 0001, Morrisville, North Carolina, United States

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Completed

Conditions: Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

First Posted Date: 2022-02-01

Last Posted Date: 2023-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 290

Registration Number: NCT05218902

Locations: 🇨🇳
Local Institution - 0001, Tianjin, Tianjin, China

Expanded Access for Anti-IL8

First Posted Date: 2022-01-27

Last Posted Date: 2022-05-16

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05210894

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Phase 1

Recruiting

Conditions: Neoplasms
Hepatic Insufficiency

Interventions: Drug: Onureg

First Posted Date: 2022-01-26

Last Posted Date: 2024-11-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT05209295

Locations: 🇦🇷
Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
🇨🇴
Instituto Nacional De Cancerologia, Bogota, Cundinamarca, Colombia
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy